Keyword search
Filter results by
Search HelpKeyword(s)
Survey or statistical program
Results
All (8)
All (8) ((8 results))
- Articles and reports: 88F0006X2007007Description:
Results from the Survey of Innovation 2003 raised some interesting questions. First, an unexpected one-third of establishments in R&D services were not innovative. According to the guidelines of the Oslo Manual, innovative establishments are those that introduced a new or significantly improved product or process on to the market or into production, within a specified interval. Second, many of these non-innovative establishments indicated that satisfying existing customers was irrelevant to their firms success. This was very different response from all other types of firms.
This working paper provides a potential explanation of these unexpected results, as well as an overview of available information on establishments in R&D services (NAICS 5417) in the context of professional services generally. The paper assembles descriptive data to show that non-innovative establishments in R&D services differ significantly from other non-innovative establishments and, while not innovative, they are nevertheless highly inventive. It presents some evidence to suggest that they are venture firms (firms relying on infusions of investment capital rather than revenues from sales to sustain their operations) and proposes a specific set of indicators that would facilitate resolution of the nature of firms in this industry group.
Release date: 2007-12-20 - Articles and reports: 88F0006X2007006Description:
This descriptive working paper provides highlights from the Biotechnology Use and Development Survey 2005. Data on innovative biotechnology firms are presented by region, sectors and firm size. The data include firm revenues, R&D activities, human resources, firm financing, age of firms, country of control and the proportion of publicly traded firms.
Release date: 2007-12-05 - 3. Results of the pilot survey on nanotechnologies ArchivedArticles and reports: 88-003-X200700210323Geography: CanadaDescription:
Although nanotechnology can be thought of as a sector of its own, it is clear that nanotechnology is a cross-sector phenomenon with potentially significant impacts. Nanotechnologies can be found in areas as diverse as biotechnology and health, agriculture, electronics and computer technology, environment and energy, optics, and in materials and manufacturing.
Release date: 2007-10-09 - Articles and reports: 88-003-X200700210324Geography: CanadaDescription:
Statistics Canada is actively involved with the international community in developing statistical information on nanotechnologies. This article summarizes the ongoing work of the OECD's newly-established Working Party on Nanotechnology, with particular emphasis on the role of Statistics Canada.
Release date: 2007-10-09 - Articles and reports: 88-003-X200700210325Geography: CanadaDescription:
Innovative biotechnology firms are science-based firms which attempt to bring an application of biotechnology to the market. However, it is clear that a significant proportion of these firms derive no revenue from product sales while their products proceed through the various phases of testing and regulatory approval. In order to support their operations they must look to other sources of funding.
Release date: 2007-10-09 - Articles and reports: 88-003-X200700210326Geography: CanadaDescription:
Although private investors and government funding agencies have learned that the biotechnology sector requires a funding model different from that of traditional manufacturing, there is a paucity of empirical research investigating the links between characteristics of the funding model and firm performance. The purpose of this article is to examine which funding sources have the greatest influence on firm growth.
Release date: 2007-10-09 - Articles and reports: 88F0006X2005010Description:
This paper looks into Canadian innovative biotechnology firms' access to financing capital. Results show that over 70% of biotech firms that attempted to raise financing capital were successful. Funds were primarily sought for R&D activities and came primarily from Canadian venture capitalists. Harsher market conditions were the main reasons put forward by investors to limit or reject biotechnology firms' funding requests.
Release date: 2005-04-29 - Articles and reports: 88-003-X20040026930Geography: CanadaDescription:
Biotechnology activity in Canada is flourishing. The total number of biotechnology firms has been continually increasing in recent years. This expansion can also be observed from the changes in revenues generated by biotechnology. Research and development (R&D) efforts are starting to bear fruit and this is reflected in the revenue ratio on R&D.
Release date: 2004-06-30
Data (0)
Data (0) (0 results)
No content available at this time.
Analysis (8)
Analysis (8) ((8 results))
- Articles and reports: 88F0006X2007007Description:
Results from the Survey of Innovation 2003 raised some interesting questions. First, an unexpected one-third of establishments in R&D services were not innovative. According to the guidelines of the Oslo Manual, innovative establishments are those that introduced a new or significantly improved product or process on to the market or into production, within a specified interval. Second, many of these non-innovative establishments indicated that satisfying existing customers was irrelevant to their firms success. This was very different response from all other types of firms.
This working paper provides a potential explanation of these unexpected results, as well as an overview of available information on establishments in R&D services (NAICS 5417) in the context of professional services generally. The paper assembles descriptive data to show that non-innovative establishments in R&D services differ significantly from other non-innovative establishments and, while not innovative, they are nevertheless highly inventive. It presents some evidence to suggest that they are venture firms (firms relying on infusions of investment capital rather than revenues from sales to sustain their operations) and proposes a specific set of indicators that would facilitate resolution of the nature of firms in this industry group.
Release date: 2007-12-20 - Articles and reports: 88F0006X2007006Description:
This descriptive working paper provides highlights from the Biotechnology Use and Development Survey 2005. Data on innovative biotechnology firms are presented by region, sectors and firm size. The data include firm revenues, R&D activities, human resources, firm financing, age of firms, country of control and the proportion of publicly traded firms.
Release date: 2007-12-05 - 3. Results of the pilot survey on nanotechnologies ArchivedArticles and reports: 88-003-X200700210323Geography: CanadaDescription:
Although nanotechnology can be thought of as a sector of its own, it is clear that nanotechnology is a cross-sector phenomenon with potentially significant impacts. Nanotechnologies can be found in areas as diverse as biotechnology and health, agriculture, electronics and computer technology, environment and energy, optics, and in materials and manufacturing.
Release date: 2007-10-09 - Articles and reports: 88-003-X200700210324Geography: CanadaDescription:
Statistics Canada is actively involved with the international community in developing statistical information on nanotechnologies. This article summarizes the ongoing work of the OECD's newly-established Working Party on Nanotechnology, with particular emphasis on the role of Statistics Canada.
Release date: 2007-10-09 - Articles and reports: 88-003-X200700210325Geography: CanadaDescription:
Innovative biotechnology firms are science-based firms which attempt to bring an application of biotechnology to the market. However, it is clear that a significant proportion of these firms derive no revenue from product sales while their products proceed through the various phases of testing and regulatory approval. In order to support their operations they must look to other sources of funding.
Release date: 2007-10-09 - Articles and reports: 88-003-X200700210326Geography: CanadaDescription:
Although private investors and government funding agencies have learned that the biotechnology sector requires a funding model different from that of traditional manufacturing, there is a paucity of empirical research investigating the links between characteristics of the funding model and firm performance. The purpose of this article is to examine which funding sources have the greatest influence on firm growth.
Release date: 2007-10-09 - Articles and reports: 88F0006X2005010Description:
This paper looks into Canadian innovative biotechnology firms' access to financing capital. Results show that over 70% of biotech firms that attempted to raise financing capital were successful. Funds were primarily sought for R&D activities and came primarily from Canadian venture capitalists. Harsher market conditions were the main reasons put forward by investors to limit or reject biotechnology firms' funding requests.
Release date: 2005-04-29 - Articles and reports: 88-003-X20040026930Geography: CanadaDescription:
Biotechnology activity in Canada is flourishing. The total number of biotechnology firms has been continually increasing in recent years. This expansion can also be observed from the changes in revenues generated by biotechnology. Research and development (R&D) efforts are starting to bear fruit and this is reflected in the revenue ratio on R&D.
Release date: 2004-06-30
Reference (0)
Reference (0) (0 results)
No content available at this time.
- Date modified: